Skip to content

Study · Randomized controlled trial · n = 41 · 2025

9 results

Efficacy and safety of once-weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT-2 trial.

Yamauchi T, Asakura T, Shingaki T, Oura T, Katagiri H

Diabetes, obesity & metabolism9 Jun 2025Cited by 5 (Europe PMC)

PMID40490415 (opens in a new tab)PMCIDPMC12232350 (opens in a new tab)DOI10.1111/dom.16500 (opens in a new tab)PepBankPUB-40490415
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity and type 2 diabetes, tirzepatide 10 mg reduced body weight significantly more than placebo at week 72.

    In plain wordsIn Japanese adults with obesity and type 2 diabetes, tirzepatide 10 mg led to more weight loss than placebo after 72 weeks.

    Peptide
    Tirzepatide
    Outcome
    DecreasePercent body weight change at week 72 (10 mg)
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 mg · 72 weeksAs given in this study (human).

    Measurements

    Mean percent change in body weight
    −12.4%
    tirzepatide 10 mg, week 72

    Source sentences

    Summary
    The mean percent change (standard error) in body weight from baseline to week 72 was statistically significantly greater for both tirzepatide 10 mg (p = 0.001) and 15 mg (p = 0.013) compared with placebo: -12.4% (1.8%) and -10.2% (1.8%), respectively, compared with -3.5% (1.8%).
    2 context sentences
    Summary · context
    This subpopulation analysis of 41 Japanese participants from three clinical trial sites in the SURMOUNT-2 trial evaluated the efficacy and safety of tirzepatide as an adjunct to lifestyle interventions in adults with body mass index ≥27 kg/m2 and a diagnosis of T2D with glycated haemoglobin ≥7% to ≤10%.
    Summary · context
    Coprimary endpoints were mean percent change in body weight and proportion of participants who achieved ≥5% body weight reduction at week 72.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity and type 2 diabetes, tirzepatide 15 mg reduced body weight significantly more than placebo at week 72.

    In plain wordsIn Japanese adults with obesity and type 2 diabetes, tirzepatide 15 mg led to more weight loss than placebo after 72 weeks.

    Peptide
    Tirzepatide
    Outcome
    DecreasePercent body weight change at week 72 (15 mg)
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    15 mg · 72 weeksAs given in this study (human).

    Measurements

    Mean percent change in body weight
    −10.2%
    tirzepatide 15 mg, week 72

    Source sentences

    Summary
    The mean percent change (standard error) in body weight from baseline to week 72 was statistically significantly greater for both tirzepatide 10 mg (p = 0.001) and 15 mg (p = 0.013) compared with placebo: -12.4% (1.8%) and -10.2% (1.8%), respectively, compared with -3.5% (1.8%).
    2 context sentences
    Summary · context
    This subpopulation analysis of 41 Japanese participants from three clinical trial sites in the SURMOUNT-2 trial evaluated the efficacy and safety of tirzepatide as an adjunct to lifestyle interventions in adults with body mass index ≥27 kg/m2 and a diagnosis of T2D with glycated haemoglobin ≥7% to ≤10%.
    Summary · context
    Coprimary endpoints were mean percent change in body weight and proportion of participants who achieved ≥5% body weight reduction at week 72.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity and type 2 diabetes, 85.7% reached at least 5% body weight reduction at week 72 with tirzepatide 10 mg, versus 46.2% with placebo.

    In plain wordsIn Japanese adults with obesity and type 2 diabetes, 85.7% on tirzepatide 10 mg lost at least 5% of body weight, versus 46.2% on placebo.

    Peptide
    Tirzepatide
    Outcome
    IncreaseProportion with body weight reduction of 5% or more (10 mg)
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 mg · 72 weeksAs given in this study (human).

    Measurements

    Participants with weight reduction of 5% or more
    85.7%
    tirzepatide 10 mg, week 72

    Source sentences

    Summary
    At week 72, 85.7% and 78.6% of participants in the tirzepatide 10 mg and 15 mg groups, respectively, had a body weight reduction of ≥5%, versus 46.2% of participants receiving placebo.
    2 context sentences
    Summary · context
    This subpopulation analysis of 41 Japanese participants from three clinical trial sites in the SURMOUNT-2 trial evaluated the efficacy and safety of tirzepatide as an adjunct to lifestyle interventions in adults with body mass index ≥27 kg/m2 and a diagnosis of T2D with glycated haemoglobin ≥7% to ≤10%.
    Summary · context
    Coprimary endpoints were mean percent change in body weight and proportion of participants who achieved ≥5% body weight reduction at week 72.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity and type 2 diabetes, 78.6% reached at least 5% body weight reduction at week 72 with tirzepatide 15 mg, versus 46.2% with placebo.

    In plain wordsIn Japanese adults with obesity and type 2 diabetes, 78.6% on tirzepatide 15 mg lost at least 5% of body weight, versus 46.2% on placebo.

    Peptide
    Tirzepatide
    Outcome
    IncreaseProportion with body weight reduction of 5% or more (15 mg)
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    15 mg · 72 weeksAs given in this study (human).

    Measurements

    Participants with weight reduction of 5% or more
    78.6%
    tirzepatide 15 mg, week 72

    Source sentences

    Summary
    At week 72, 85.7% and 78.6% of participants in the tirzepatide 10 mg and 15 mg groups, respectively, had a body weight reduction of ≥5%, versus 46.2% of participants receiving placebo.
    2 context sentences
    Summary · context
    This subpopulation analysis of 41 Japanese participants from three clinical trial sites in the SURMOUNT-2 trial evaluated the efficacy and safety of tirzepatide as an adjunct to lifestyle interventions in adults with body mass index ≥27 kg/m2 and a diagnosis of T2D with glycated haemoglobin ≥7% to ≤10%.
    Summary · context
    Coprimary endpoints were mean percent change in body weight and proportion of participants who achieved ≥5% body weight reduction at week 72.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity and type 2 diabetes, tirzepatide was associated with reductions in glycemic parameters.

    In plain wordsIn Japanese adults with obesity and type 2 diabetes, tirzepatide was associated with lower blood sugar measures.

    Peptide
    Tirzepatide
    Outcome
    DecreaseGlycemic parameters
    Study

    n = 41

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mg or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Reductions in glycemic parameters, waist circumference and systolic blood pressure, as well as numerical improvements in the lipid profile, were also observed with tirzepatide.
    2 context sentences
    Summary · context
    This subpopulation analysis of 41 Japanese participants from three clinical trial sites in the SURMOUNT-2 trial evaluated the efficacy and safety of tirzepatide as an adjunct to lifestyle interventions in adults with body mass index ≥27 kg/m2 and a diagnosis of T2D with glycated haemoglobin ≥7% to ≤10%.
    Summary · context
    Coprimary endpoints were mean percent change in body weight and proportion of participants who achieved ≥5% body weight reduction at week 72.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity and type 2 diabetes, tirzepatide was associated with a reduction in waist circumference.

    In plain wordsIn Japanese adults with obesity and type 2 diabetes, tirzepatide was associated with a smaller waist size.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWaist circumference
    Study

    n = 41

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 mg or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Reductions in glycemic parameters, waist circumference and systolic blood pressure, as well as numerical improvements in the lipid profile, were also observed with tirzepatide.
    2 context sentences
    Summary · context
    This subpopulation analysis of 41 Japanese participants from three clinical trial sites in the SURMOUNT-2 trial evaluated the efficacy and safety of tirzepatide as an adjunct to lifestyle interventions in adults with body mass index ≥27 kg/m2 and a diagnosis of T2D with glycated haemoglobin ≥7% to ≤10%.
    Summary · context
    Coprimary endpoints were mean percent change in body weight and proportion of participants who achieved ≥5% body weight reduction at week 72.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity and type 2 diabetes, tirzepatide was associated with a reduction in systolic blood pressure.

    In plain wordsIn Japanese adults with obesity and type 2 diabetes, tirzepatide was associated with lower systolic blood pressure.

    Peptide
    Tirzepatide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n = 41

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    10 mg or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Reductions in glycemic parameters, waist circumference and systolic blood pressure, as well as numerical improvements in the lipid profile, were also observed with tirzepatide.
    2 context sentences
    Summary · context
    This subpopulation analysis of 41 Japanese participants from three clinical trial sites in the SURMOUNT-2 trial evaluated the efficacy and safety of tirzepatide as an adjunct to lifestyle interventions in adults with body mass index ≥27 kg/m2 and a diagnosis of T2D with glycated haemoglobin ≥7% to ≤10%.
    Summary · context
    Coprimary endpoints were mean percent change in body weight and proportion of participants who achieved ≥5% body weight reduction at week 72.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with obesity and type 2 diabetes, tirzepatide was associated with numerical improvements in the lipid profile.

    In plain wordsIn Japanese adults with obesity and type 2 diabetes, tirzepatide was linked to small numerical improvements in blood fats.

    Peptide
    Tirzepatide
    Outcome
    MixedLipid profile
    Study

    n = 41

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    10 mg or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Reductions in glycemic parameters, waist circumference and systolic blood pressure, as well as numerical improvements in the lipid profile, were also observed with tirzepatide.
    2 context sentences
    Summary · context
    This subpopulation analysis of 41 Japanese participants from three clinical trial sites in the SURMOUNT-2 trial evaluated the efficacy and safety of tirzepatide as an adjunct to lifestyle interventions in adults with body mass index ≥27 kg/m2 and a diagnosis of T2D with glycated haemoglobin ≥7% to ≤10%.
    Summary · context
    Coprimary endpoints were mean percent change in body weight and proportion of participants who achieved ≥5% body weight reduction at week 72.
  9. 09HumanRandomized controlled trialSafety outcome

    In Japanese adults with obesity and type 2 diabetes, no new safety concerns were identified with tirzepatide.

    In plain wordsIn Japanese adults with obesity and type 2 diabetes, no new safety concerns were found with tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeSafety profile
    Study

    n = 41

    Outcome group
    Adverse events · Whole body
    Studied dose
    10 mg or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    No new safety concerns were identified.
    2 context sentences
    Summary · context
    This subpopulation analysis of 41 Japanese participants from three clinical trial sites in the SURMOUNT-2 trial evaluated the efficacy and safety of tirzepatide as an adjunct to lifestyle interventions in adults with body mass index ≥27 kg/m2 and a diagnosis of T2D with glycated haemoglobin ≥7% to ≤10%.
    Summary · context
    Coprimary endpoints were mean percent change in body weight and proportion of participants who achieved ≥5% body weight reduction at week 72.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.